Positive Data for Protara Therapeutics in Bladder Cancer Trial

3D Illustration of Human Urinary System Bladder

Protara Therapeutics (Nasdaq: TARA) has released positive data from its ongoing clinical program of TARA-002, the company’s investigational cell-based therapy, being evaluated in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC). TARA-002 is targeting NMIBC including Bacillus Calmette-Guérin (BCG)-Unresponsive, BCG-Experienced and BCG-Naïve patient populations.

Protara expects to share preliminary results from a pre-planned risk-benefit analysis of 10 patients in its ADVANCED-2 Phase 2 clinical trial of TARA-002 who are six-month evaluable in the second half of 2024.

“We are highly encouraged by these early results observed in these three-month evaluable patients across our ADVANCED-1 and ADVANCED-2 clinical trials, which clearly demonstrate TARA-002’s activity in both BCG-Unresponsive and BCG-Naïve patients. We look forward to sharing data from post-reinduction, six-month evaluable patients in our ADVANCED-2 trial in the second half of 2024,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.

TARA-002 has demonstrated encouraging anti-tumor activity coupled with a favorable safety profile and a mode of administration that is both convenient and familiar to urologists.

About Protara Therapeutics, Inc.

Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.

Share This Article

 

About the Author

Positive Data for Protara Therapeutics in Bladder Cancer Trial

Catie Corcoran

Biotech Editor